Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)

Daniel Marbach; Jurriaan Brouer-Visser; Laura Brennan; Sabine Wilson; Iakov I Davydov; Nicolas Staedler; José Duarte; Iris Martinez Quetglas; Eveline Nüesch; Marta Cañamero; Evelyne Chesné; George Au-Yeung; Erika Hamilton; Stephanie Lheureux; Debra L Richardson; Iben Spanggaard; Bruno Gomes; Izolda Franjkovic; Mark DeMario; Martin Kornacker; Katharina Lechner

doi:10.1101/2024.07.28.24309665

Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)

View ORCID ProfileDaniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, Sabine Wilson, View ORCID ProfileIakov I Davydov, Nicolas Staedler, José Duarte, Iris Martinez Quetglas, Eveline Nüesch, Marta Cañamero, Evelyne Chesné, George Au-Yeung, Erika Hamilton, Stephanie Lheureux, Debra L Richardson, Iben Spanggaard, Bruno Gomes, Izolda Franjkovic, Mark DeMario, Martin Kornacker, Katharina Lechner

doi: https://doi.org/10.1101/2024.07.28.24309665

Daniel Marbach

1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Daniel Marbach
For correspondence: daniel.marbach.dm1@roche.com

Jurriaan Brouer-Visser

2Roche Pharma Research and Early Development, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd, New York, NY, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Laura Brennan

2Roche Pharma Research and Early Development, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd, New York, NY, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sabine Wilson

1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Iakov I Davydov

1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Iakov I Davydov

Nicolas Staedler

1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

José Duarte

1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Iris Martinez Quetglas

1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Eveline Nüesch

3Product Development, Data Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marta Cañamero

4Roche Pharma Research and Early Development, Roche Innovation Center Munich, F. Hoffmann-La Roche Ltd, Penzberg, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Evelyne Chesné

1Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

George Au-Yeung

5Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Erika Hamilton

6Sarah Cannon Research Institute, Nashville, TN, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stephanie Lheureux

7Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Debra L Richardson

8Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Iben Spanggaard

9Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bruno Gomes

10Roche Pharma Research and Early Development, Oncology Early Clinical Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Izolda Franjkovic

4Roche Pharma Research and Early Development, Roche Innovation Center Munich, F. Hoffmann-La Roche Ltd, Penzberg, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark DeMario

2Roche Pharma Research and Early Development, Roche Innovation Center New York, F. Hoffmann-La Roche Ltd, New York, NY, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin Kornacker

10Roche Pharma Research and Early Development, Oncology Early Clinical Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Katharina Lechner

4Roche Pharma Research and Early Development, Roche Innovation Center Munich, F. Hoffmann-La Roche Ltd, Penzberg, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

Article usage

Article usage: July 2024 to November 2024

	Abstract	Full	Pdf
Jul 2024	884	1	25
Aug 2024	151	20	51
Sep 2024	79	3	55
Oct 2024	75	5	35
Nov 2024	23	0	2

View the discussion thread.

PreviousNext

Posted July 29, 2024.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)

Message Subject (Your Name) has forwarded a page to you from medRxiv

Message Body (Your Name) thought you would like to see this page from the medRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)

Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, Sabine Wilson, Iakov I Davydov, Nicolas Staedler, José Duarte, Iris Martinez Quetglas, Eveline Nüesch, Marta Cañamero, Evelyne Chesné, George Au-Yeung, Erika Hamilton, Stephanie Lheureux, Debra L Richardson, Iben Spanggaard, Bruno Gomes, Izolda Franjkovic, Mark DeMario, Martin Kornacker, Katharina Lechner

medRxiv 2024.07.28.24309665; doi: https://doi.org/10.1101/2024.07.28.24309665

Share This Article: